FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman
Approval clears way for expanded U-M clinical trial role.
For nearly two years, University of Michigan neurologist Eva Feldman, M.D., Ph.D. has led the nation’s first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig’s disease.
Now, a new approval from the U.S. Food and Drug Administration paves the way for U-M to become the second site in the trial, pending approval of the U-M Institutional Review Board. To date, the first phase of the trial has taken place at Emory University, with Feldman serving as principal investigator.
The FDA approval of a Phase II trial was announced today by Neuralstem, the company whose product the trial is testing. The Phase II trial will continue to evaluate the safety of the stem cell injections, delivered directly into patients’ spinal cords in escalating doses of up to 400,000 cells per injection, with a maximum of 40 injections. It will also assess any signs that the injections might be impacting patients’ ALS symptoms or progression.
Feldman serves as an unpaid consultant to the company, and has led the analysis of results from the Phase I trial. In data presented last year, spinal cord injections of up to 100,000 cells were delivered safely and tolerated well -- with possible signs that in one subgroup of participants, ALS progression may have been interrupted.
New Taubman Prize trophy debuts
The new trophy for the Taubman Prize for Excellence in Translational Medical Research, which was designed in consultation with institute founder Mr. A. Alfred Taubman, was presented at the institute's Oct. 11 symposium. The modern sculpture was created using a novel 3D printing technique.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
U-M offers new early detection prostate cancer test
Research by Taubman Scholar Dr. Arul Chinnaiyan has let to the development of a new test for prostate cancer that is far more accurate than the standard PSA test, the University of Michigan has announced.
Click here to read more.
news & events
Is there a link between tonsils and psoriasis?
Trial tested the effect of tonsillectomy on the skin disease
Taubman Emerging Scholar Dr. Johann Gudjonsson and colleagues found that people who had their tonsils removed showed improvment.
Click here to read the entire story
Fall Visiting Professor Lectures schedule
Distinguished guest speakers include experts in lung, muscle and nerve diseases
Click here for the lineup
Breast cancer clinical trial enrolling patients
Research by Taubman Scholar Dr. Max Wicha into breast cancer stem cells is the basis for a new human clinical trial of the drug Reparixin, which scientists hope will curb the growth of the tumor-fueling cells.